Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | SERPINE1 | P05121 | 5/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246511 | 0.92 | TRPV1 (0.55) | TRPV1CYP19A1SERPINE1EPHX1P2RX4 | |
| SCHEMBL22697670 | 0.88 | TRPV1 (0.69) | TRPV1CYP19A1SERPINE1EPHX1P2RX4 | |
| SCHEMBL38354 | 0.84 | TRPV1 (0.47) | TRPV1CYP19A1SERPINE1EPHX1P2RX4 | |
| SCHEMBL38821 | 0.84 | TRPV1 (0.47) | TRPV1CYP19A1SERPINE1EPHX1P2RX4 | |
| SCHEMBL12166714 | 0.82 | ALDH1A1 (0.55) | CYP19A1SERPINE1EPHX1P2RX4ALDH1A1 | |
| SCHEMBL12166539 | 0.82 | ALDH1A1 (0.55) | CYP19A1SERPINE1EPHX1P2RX4ALDH1A1 | |
| SCHEMBL12166956 | 0.82 | ALDH1A1 (0.55) | CYP19A1SERPINE1EPHX1P2RX4ALDH1A1 | |
| SCHEMBL2574092 | 0.82 | ALDH1A1 (0.55) | CYP19A1SERPINE1EPHX1P2RX4ALDH1A1 | |
| SCHEMBL13246428 | 0.82 | SMN1; SMN2 (0.57) | CYP19A1SERPINE1EPHX1ALDH1A1HPGD | |
| SCHEMBL2573844 | 0.82 | SMN1; SMN2 (0.57) | CYP19A1SERPINE1EPHX1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731991-B2 | Augmenting moieties for anti-inflammatory compounds | LEHIGH UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731991-B2 | Augmenting moieties for anti-inflammatory compounds | LTC4S, VCAM1, PTGES | TRPV1 17/4885CYP19A1 1032/4885SERPINE1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.